Recent Advances in Molecular Mechanism of Metformin against Gastrointestinal Cancer in Type 2 Diabetics

doi:10.12114/j.issn.1007-9572.2021.00.513

Abstract

Abstract: The morbidity and mortality rates of gastrointestinal cancers are increasing with the aging of population in China，such as esophageal cancer，gastric cancer，pancreatic cancer and colorectal cancer，seriously endangering people's health.Metformin has been used for type 2 diabetes since 1995，and has become a first-line drug for type 2 diabetes for its safe and stable anti-hyperglycemic and cardiovascular protective effects favored by endocrinologists.Meanwhile，epidemiological and clinical studies at home and abroad have confirmed that metformin can reduce the incidence rate of various tumors and improve the prognosis in type 2 diabetics，suggesting that chemoprophylaxis of gastrointestinal cancer may be a breakthrough obtained in cancer chemoprophylaxis.In this paper，the molecular mechanism of metformin against gastrointestinal cancer in diabetics was reviewed.

Key words: Metformin, Digestive system neoplasms, Diabetes mellitus

摘要： 在我国，随着人口老龄化进程加剧，消化系统肿瘤的发生率及死亡率不断上升，如食管癌、胃癌、胰腺癌和结直肠癌等，严重危害人们身体健康。自1995年二甲双胍用于治疗2型糖尿病以来，其因安全稳定的降糖效果及心血管保护作用而受到内分泌专家的青睐，并成为了2型糖尿病患者的一线治疗药物。同时，国内外流行病学与临床观察研究均证实二甲双胍不仅能够降低糖尿病患者多种肿瘤的发生率，而且还能改善患者的预后，提示肿瘤的化学预防有可能在胃肠道肿瘤中取得突破。本文对二甲双胍抗糖尿病患者消化系统肿瘤的分子机制进行综述。

关键词: 二甲双胍, 消化系统肿瘤, 糖尿病

TAN Zhiqiang,HE Li,JIANG Yanxia. Recent Advances in Molecular Mechanism of Metformin against Gastrointestinal Cancer in Type 2 Diabetics　[J]. Chinese General Practice, 2021, 24(21): 2744-2748. DOI: 10.12114/j.issn.1007-9572.2021.00.513.
谭志强,何立,江妍霞. 二甲双胍抗糖尿病患者消化系统肿瘤分子机制的研究进展[J]. 中国全科医学, 2021, 24(21): 2744-2748. DOI: 10.12114/j.issn.1007-9572.2021.00.513.

References

［1］SAEDI E，GHEINI M R，FAIZ F，et al．Diabetes mellitus and cognitive impairments［J］．World J Diabetes，2016，7（17）：412-422.
［2］HAMEED A，ALI J，MUNAWAR K，et al．Characteristics and outcomes of patients with multiple myeloma：data from a developing country［J］．Med J Islam Repub Iran，2018，32：1．DOI：10.14196/mjiri.32.1.
［3］HUSSAIN A，ALMENFI H F，ALMEHDEWI A M，et al．Laboratory features of newly diagnosed multiple myeloma patients［J］．Cureus，2019，11（5）：e4716．DOI：10.7759/cureus.4716.
［4］EVANS J M，DONNELLY L A，EMSLIE-SMITH A M，et al．Metformin and reduced risk of cancer in diabetic patients［J］．BMJ，2005，330（7503）：1304-1305．DOI：10.1136/bmj.38415.708634.f7.
［5］MOHTY M，CAVO M，FINK L，et al．Understanding mortality in multiple myeloma：findings of a European retrospective chart review［J］．Eur J Haematol，2019，103（2）：107-115．DOI：10.1111/ejh.13264.
［6］BRIDGEMAN S C，ELLISON G C，MELTON P E，et al．Epigenetic effects of metformin：from molecular mechanisms to clinical implications［J］．Diabetes Obes Metab，2018，20（7）：1553-1562.
［7］PRYOR R，CABREIRO F.Repurposing metformin：an old drug with new tricks in its binding pockets［J］．Biochem J，2015，471（3）：307-322.
［8］SAINI N，YANG X.Metformin as an anti-cancer agent：actions and mechanisms targeting cancer stem cells［J］．Acta Biochim Biophys Sin（Shanghai），2018，50（2）：133-143．DOI：10.1093/abbs/gmx106.
［9］SUN Y，TAO C，HUANG X，et al．Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway［J］．Onco Targets Ther，2016，9：2845-2853．DOI：10.2147/ott.s99770.
［10］WANG K.The ubiquitous existence of MicroRNA in body fluids［J］．Clin Chem，2017，63（3）：784-785．DOI：10.1373/clinchem.2016.267625.
［11］KIM M Y，KIM Y S，KIM M，et al．Metformin inhibits cervical cancer cell proliferation via decreased AMPK O-GlcNAcylation［J］．Anim Cells Syst （Seoul），2019，23（4）：302-309.
［12］KIM H J，LEE S，CHUN K H，et al．Metformin reduces the risk of cancer in patients with type 2 diabetes：an analysis based on the Korean National Diabetes Program Cohort［J］．Medicine，2018，97（8）：e0036．DOI：10.1097/MD.0000000000010036.
［13］XIE W，WANG L，SHENG H，et al．Metformin induces growth inhibition and cell cycle arrest by upregulating MicroRNA34a in renal cancer cells［J］．Med Sci Monit，2017，23：29-37．DOI：10.12659/msm.898710.
［14］LI Y，LUO J，LIN M T，et al．Co-delivery of metformin enhances the antimultidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment［J］．Mol Pharm，2019，16（7）：2966-2979．DOI：10.1021/acs.molpharmaceut.9b00199.
［15］LI P D，LIU Z，CHENG T T，et al．Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin［J］．Oncotarget，2017，8（37）：62057-62068．DOI：10.18632/oncotarget.18907.
［16］杨川，姚凯文，张华.二甲双胍抗肿瘤与K-ras突变的相关性［J］．现代肿瘤医学，2016，24（7）：1172-1174.
YANG C，YAO K W，ZHANG H.The correlation between antitumor effects of metformin and K-ras gene mutation［J］．Journal of Modern Oncology，2016，24（7）：1172-1174.
［17］HONJO S，AJANI J A，SCOTT A W，et al．Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer［J］．Int J Oncol，2014，45（2）：567-574．DOI：10.3892/ijo.2014.2450.
［18］WANG L，LI K，LIN X，et al．Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis［J］．Cancer Lett，2019，450：22-31．DOI：10.1016/j.canlet.2019.02.014.
［19］WANG Q L，SANTONI G，NESS-JENSEN E，et al．Association between metformin use and risk of esophageal squamous cell carcinoma in a population-based cohort study［J］．Am J Gastroenterol，2020，115（1）：73-78．DOI：10.14309/ajg.0000000000000478.
［20］QUEIROZ E A，PUUKILA S，EICHLER R，et al．Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress，AMPK and FOXO3a in MCF-7 breast cancer cells［J］．PLoS One，2014，9（5）：e98207．DOI：10.1371/journal.pone.0098207.
［21］DOWLING R J，ZAKIKHANI M，FANTUS I G，et al．Meformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells［J］．Cancer Res，2007，67（22）：10804-10812.
［22］ALALEM M，RAY A，RAY B K.Metformin induces degradation of mTOR protein in breast cancer cells［J］．Cancer Med，2016，5（11）：3194-3204．DOI：10.1002/cam4.896.
［23］RODRIGEZ-GOZALEZ A，LIN T，IKEDA A K，et al．Role of the aggre-some pathway in cancer：tangeting histone deacetylase 6-dependent protein degradation［J］．Cancer Res，2008，68（8）：2557-2560.
［24］JOO M K，PARK J J，CHUN H J.Additional benefits of routine drugs on gastrointestinal cancer：statins，metformin，and proton pump inhibitors［J］．Dig Dis，2018，36（1）：1-14．DOI：10.1159/000480149.
［25］FUJIHARA S，KATO K，MORISHITA A，et al．Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo［J］．Int J Oncol，2015，46（5）：2172-2180.
［26］CHEN W Q，ZHENG R S，BAADE P D，et al．Cancer statistics in China，2015［J］．CA Cancer J Clin，2016，66（2）：115-132.DOI：10.3322/caac.21338．
［27］DAUGAN M，DUFA? W A，D'HAYER B，et al．Metformin：an anti-diabetic drug to fight cancer［J］．Pharmacol Res，2016，113（Pt A）：675-685.
［28］GUO H，KONG W，ZHANG L，et al．Reversal of obesity-driven aggressiveness of endometrial cancer by metformin［J］．Am J Cancer Res，2019，9（10）：2170-2193.
［29］GAO L，LV G，LI R，et al．Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation［J］．Cancer Lett，2019，454：215-223．DOI：10.1016/j.canlet.2019.04.009.
［30］HAN G，GONG H，WANG Y，et al．AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell［J］．Cancer Biol Ther，2015，16（1）：77-87．DOI：10.4161/15384047.2014.987021.
［31］LIU S，YUE C，CHEN H Q，et al．Metformin promotes Beclin1-dependent autophagy to inhibit the progression of gastric cancer［J］．Onco Targets Ther，2020，13：4445-4455.
［32］CHEUNG K S，CHAN E W，WONG A Y S，et al．Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication［J］．J Natl Cancer Inst，2019，111（5）：484-489．DOI：10.1093/jnci/djy144.
［33］KIM Y I，KIM S Y，CHO S J，et al．Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment：a nationwide cohort study［J］．Aliment Pharmacol Ther，2014，39（8）：854-863．DOI：10.1111/apt.12660.
［34］ZHOU X L，XUE W H，DING X F，et al．Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus：a meta-analysis of cohort studies［J］．Oncotarget，2017，8（33）：55622-55631.
［35］WANG Y，WU Z，HU L.Epithelial-mesenchymal transition phenotype，metformin，and survival for colorectal cancer patients with diabetes mellitus Ⅱ［J］．Gastroenterol Res Pract，2017，2017：2520581．DOI：10.1155/2017/2520581.
［36］WANG Y，WU Z，HU L.The regulatory effects of metformin on the ［SNAIL/miR-34］：［ZEB/miR-200］ system in the epithelial-mesenchymal transition（EMT） for colorectal cancer（CRC）［J］．Eur J Pharmacol，2018，834：45-53．DOI：10.1016/j.ejphar.2018.07.006.
［37］HUANG W S，LIN C T，CHEN C N，et al．Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression［J］．J Cell Biochem，2018，119（8）：6943-6952．DOI：10.1002/jcb.26898.
［38］NIE Z，ZHU H，GU M.Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin：a meta-analysis［J］．Pharm Biol，2016，54（11）：2636-2642．DOI：10.1080/13880209.2016.1176057.
［39］HOSONO K，ENDO H，TAKAHASHI H，et al．Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial［J］．Cancer Prev Res：Phila，2010，3（9）：1077-1083．DOI：10.1158/1940-6207.capr-10-0186.
［40］MIRANDA V C，BRAGHIROLI M I，FARIA L D，et al．Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer［J］．Clin Colorectal Cancer，2016，15（4）：321-328.e1．DOI：10.1016/j.clcc.2016.04.011.
［41］RAHIB L，SMITH B D，AIZENBERG R，et al．Projecting cancer incidence and deaths to 2030：the unexpected burden of thyroid，liver，and pancreas cancers in the United States［J］．Cancer Res，2014，74（11）：2913-2921.
［42］CIFARELLI V，LASHINGER L M，DEVLIN K L，et al．Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms［J］．Diabetes，2015，64（5）：1632-1642．DOI：10.2337/db14-1132.
［43］LI Y，LI L，ZHANG G，et al．Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis［J］．Invest New Drugs，2018，36（1）：20-27．DOI：10.1007/s10637-017-0508-2.
［44］CHAITEERAKIJ R，PETERSEN G M，BAMLET W R，et al．Metformin use and survival of patients with pancreatic cancer：a cautionary lesson［J］．J Clin Oncol，2016，34（16）：1898-1904．DOI：10.1200/jco.2015.63.3511.
［45］AMIN S，MHANGO G，LIN J，et al．Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes：a propensity score analysis［J］．Am J Gastroenterol，2016，111（9）：1350-1357．DOI：10.1038/ajg.2016.288.
［46］PUSCEDDU S，VERNIERI C，DI MAIO M，et al．Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues［J］．Gastroenterology，2018，155（2）：479-489.e7．DOI：10.1053/j.gastro.2018.04.010.
［47］EL-SERAG H B.Hepatocellular carcinoma：recent trends in the United States［J］．Gastroenterology，2004，127（5 Suppl 1）：S27-34.
［48］DECENSI A，PUNTONI M，GOODWIN P，et al．Metformin and cancer risk in diabetic patients：a systematic review and meta-analysis［J］．Cancer Prev Res Phila Pa，2010，3（11）：1451-1461．DOI：10.1158/1940-6207.CAPR-10-0157.
［49］EL-SERAG H B，RICHARDSON P A，EVERHART J E.The role of diabetes in hepatocellular carcinoma：a case-control study among United States Veterans［J］．Am J Gastroenterol，2001，96（8）：2462-2467.
［50］RAHMAN M T，NAKAYAMA K，ISHIKAWA M，et al．Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer［J］．Oncology，2013，84（3）：166-173．DOI：10.1159/000342967.
［51］SWIERCZYNSKI J，SLEDZINSKI T.Metabolic and regulatory function of fatty acid synthase［J］．Postepy Biochem，2012，58（2）：175-185.
［52］ZHENG L，YANG W，WU F，et al．Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma［J］．Clin Cancer Res，2013，19（19）：5372-5380．DOI：10.1158/1078-0432.ccr-13-0203.
［53］SHI W Y，XIAO D，WANG L，et al．Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy［J］．Cell Death Dis，2012，3：e275．DOI：10.1038/cddis.2012.13.
［54］彭晓韧，刘燕，邹大进，等，二甲双胍对人肝癌细胞HepG2增殖及脂肪酸合酶的影响［J］．医学研究生学报，2015，28（4）：360-364.
［55］SUN Y，TAO C，HUANG X，et al．Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway［J］．Onco Targets Ther，2016，9：2845-2853．DOI：10.2147/ott.s99770.
［56］MIYOSHI H，KATO K，IWAMA H，et al．Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo［J］．Int J Oncol，2014，45（1）：322-332．DOI：10.3892/ijo.2014.2419.
［57］SINGH S，SINGH P P，SINGH A G，et al．Anti-diabetic medications and the risk of hepatocellular cancer：a systematic review and meta-analysis［J］．Am J Gastroenterol，2013，108（6）：881-892．DOI：10.1038/ajg.2013.5.

[1]	Gechu SHANG, Xiaoyong WANG, Yan GAO. Rosuvastatin Calcium with Metformin Improves Kidney Function in a Rat Model of Diabetes by Regulating the Expression of Glucose Transporter 4 [J]. Chinese General Practice, 2022, 25(18): 2291-2296.
[2]	Yuying CHEN, Xiaodong LI, Yunzhao TANG, Daiqing LI. Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2022, 25(15): 1888-1896,1905.
[3]	SU Peng, LIU Yukun, LIANG Xiaohua, LIU Xin, YU Yaohui, HUANG Pengfei, BAI Yuru, HE Xiaoyan, SHEN Zhihong, MA Dong. Reducing the Risk of Adverse Events in Patients with Type 2 Diabetes Who are Poorly Treated with Metformin Combined with Acarbose：Dipeptidyl Peptidase-4 Inhibitor is Better Than Insulin [J]. Chinese General Practice, 2022, 25(09): 1054-1061.
[4]	LIU Chang，ZHOU Yiling，WANG Yang，TAN Jixue，AN Kang，AN Zhenmei，HE Longtao，LI Sheyu. Knowledge，Attitude and Practice of Metformin Hydrochloride Sustained Release Tablets in Outpatients with Type 2 Diabetes Mellitus　 [J]. Chinese General Practice, 2021, 24(36): 4593-4598.
[5]	ZHANG Donghong，LI Qiang. Recent Advances in Clinical Application of GA/HbA1c Ratio　 [J]. Chinese General Practice, 2020, 23(17): 2105-2109.
[6]	HUANG Shen-an，QIAN Xia，ZHANG Li-hua，SHANG Hong-wei，XIONG Ping，FANG Nian. Efficacy of Gastroscopic Submucosal Dissection in the Adjuvant Diagnosis and Treatment of Primary Gastric Lymphoma [J]. Chinese General Practice, 2018, 21(23): 2818-2822.
[7]	HAN Hong-chao，XU Jie，WANG Ai-kun，XU Yue-chao. Clinical Study of Gastrointestinal Malignancies with VTE as the Initial Manifestation　#br# [J]. Chinese General Practice, 2018, 21(22): 2716-2719.
[8]	HE Wei-ming1，LU Guang-xing1，LIANG Bi-yu1，HE Yu-qing2，3*. Research Situation and Application Prospect of Combined Multiple Tumor Markers Detection in Digestive System Neoplasms　 [J]. Chinese General Practice, 2018, 21(14): 1750-1756.